This is a working overview of incretin, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-08-22 and is reviewed periodically as new material appears.
The distinction between established facts and open questions matters here. That the peptide binds the GLP-1 receptor and stimulates insulin release in a glucose-dependent manner is well documented. How individual variability in receptor density, gastric emptying rate, and gut microbiome composition shapes response remains an active research area. Long-term outcomes beyond five years of continuous use are not yet fully characterized in published trials, and several extension studies are ongoing.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。
In the nineteenth century numerous authors described both cretinism and myxedema, and their relationship to the thyroid. Charles Mayo coined the term hyperthyroidism in 1910. Hakaru Hashimoto documented a case of Hashimoto's thyroiditis in 1912, antibodies in this disease were demonstrated in 1956. Knowledge of the thyroid and its conditions developed throughout the late nineteenth and twentieth centuries, with many modern treatments and investigative modalities evolving throughout the mid twentieth century, including the use of radioactive iodine, thiouracil and fine needle aspiration.
Nussbaum, Louis-Frédéric and Käthe Roth. (2005). Japan encyclopedia. Cambridge: Harvard University Press. ISBN 978-0-674-01753-5; OCLC 58053128 Rickman, J. (2003). Sunset of the samurai. Military History. August, 42–49. Shinsengumihq.com, (n.d.). No sleep, no rest: Meiji law enforcement. Retrieved August 5, 2008. Vos, F., et al., Meiji, Japanese Art in Transition, Ceramics, Cloisonné, Lacquer, Prints, Organized by the Society for Japanese Art and Crafts, 's-Gravenhage, the Netherlands, Gemeentemuseum, 1987. ISBN 90-70216-03-5
== Species complex == While traditionally described as a cosmopolitan species, recent genetic research has identified Octopus vulgaris as a species complex. There are currently six recognized members of the Octopus vulgaris species complex. Each member of the complex is associated with specific geographic regions, often associated with continental coastlines.
It is particularly concerning as those consequences happen while the brain is still developing. The degree to which the sleep is disturbed and fragmented has been significantly linked to the severity of the consequences, the latter having the possibility to decrease once the sleep is improved. It is more the disruption of sleep processes than the total amount of sleep the child experience that generates the adverse consequences on the child's daytime functioning; it contributes to the hyperactivity for example. Children with OSA may experience learning and memory deficits, and OSA has been linked to lowered childhood IQ scores. Untreated OSA may prevent children from reaching their height potential.
Sources: en.wikipedia.org
=== Interdisciplinary === Interdisciplinary fields include agrochemistry, astrochemistry (and cosmochemistry), atmospheric chemistry, chemical engineering, chemical biology, chemo-informatics, environmental chemistry, geochemistry, green chemistry, immunochemistry, marine chemistry, materials science, mechanochemistry, medicinal chemistry, molecular biology, nanotechnology, oenology, pharmacology, phytochemistry, solid-state chemistry, surface science, thermochemistry, and many others.
Since Xi became general secretary, censorship has stepped up. Xi has overseen the increased coordination and consolidation of censorship authorities, raising their efficiency, and under his leadership censorship practices have tightened. Xi has called on for more positive energy at Chinese media, referring to the need for uplifting messages as opposed to critical or negative ones. In August 2013, he gave what became known as the August 19 speech, emphasizing the guiding role of ideology in propaganda. At the Symposium on News Reporting and Public Opinion in 2016, Xi stated that "party and government-owned media must hold the family name of the party" and that the state media "must embody the party's will, safeguard the party's authority". Xi's administration has overseen more Internet restrictions imposed, and is described as being "stricter across the board" on speech than previous administrations. In 2013, the State Internet Information Office summoned influential bloggers to a seminar to instruct them to avoid writing about politics, the CCP, or making statements contradicting official narratives. Many bloggers stopped writing about controversial topics, and Weibo went into decline, with much of its readership shifting to WeChat users speaking to limited social circles. The SIIO also formulated the Seven Bottom Lines, which serve as the bottom lines that internet users and social media companies in China must adhere to.
Scarring during healing can create both physical and psychological problems, and is a significant clinical burden. Collagen, for instance, is abnormally organised in scar tissue; collagen in scars is arranged in parallel bundles of collagen fibers, whilst healthy scar free tissue has a "basket weave" structure (Figure 1). The difference in collagen arrangement along with a lack of difference in the dermal tissue when healing has taken place with or without scarring is indicative of regenerative failure of normal skin. Severe scarring resulting from these collagen deposits is known as hypertrophic scarring and is of great concern worldwide with an incidence ranging from 32–72%.
Sources: en.wikipedia.org
== External links == Anatomy Atlases – Microscopic Anatomy, plate 07.141 - "Axillary Sweat Gland: Myoepithelium" Histology image: 43_13 at the University of Oklahoma Health Sciences Center - "thick skin" Histology at KUMC glands-glands09 "Simple Tubular Coiled" Costoff, A., Essentials of Human Physiology, archived from the original on 2015-11-20{{citation}}: CS1 maint: bot: original URL status unknown (link)
== Mechanism and regulation == 3-phosphoglycerate dehydrogenase works via an induced fit mechanism to catalyze the transfer of a hydride from the substrate to NAD+, a required cofactor. In its active conformation, the enzyme's active site has multiple cationic residues that likely stabilize the transition state of the reaction between the negatively charged substrate and NAD+. The positioning is such that the substrate's alpha carbon and the C4 of the nicotinamide ring are brought into a proximity that facilitates the hydride transfer producing NADH and the oxidized substrate.
2 NaN3 + 2 HNO2 → 3 N2 + 2 NO + 2 NaOH A safer modification to the above method that avoids the potential production of hydrazoic acid or nitrogen oxide fumes is that of W. F. Rinkenbach. A solution of 2.5 oz (71 g) sodium nitrite in 1 US pt (470 mL) of water is added to a stirring dispersion of 1 oz (28 g) sodium azide in 1.5 US gal (5.7 L) 10% ammonium acetate, followed by addition of 7 US fl oz (210 mL) of glacial acetic acid. The solution is allowed to stand in a warm place for an hour and disposed of.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.